Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

(2014) M Rodgers et al.   HEALTH TECHNOLOGY ASSESSMENT

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

(2012) Philip S Helliwell et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of Composite Measures for Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting

(2012) P. S. HELLIWELL et al.   JOURNAL OF RHEUMATOLOGY

Psoriatic Arthritis

(2012) M. S. Day et al.   JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study

(2011) Asta Baranauskaite et al.   ANNALS OF THE RHEUMATIC DISEASES

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

(2011) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator

(2011) Alberto Migliore et al.   CLINICAL RHEUMATOLOGY

Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone

(2011) C. F. Rosen et al.   RHEUMATOLOGY

Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis

(2011) L. Bojke et al.   RHEUMATOLOGY

Clinical outcomes in psoriatic arthritis: A systematic literature review

(2011) Penélope Esther Palominos et al.   ARTHRITIS CARE & RESEARCH

Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study

(2010) F. Atzeni et al.   ANNALS OF THE RHEUMATIC DISEASES

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

(2010) Hideshi Torii et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature

(2010) S Prey et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue

(2008) A W R van Kuijk et al.   ANNALS OF THE RHEUMATIC DISEASES

Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis

(2008) A Spadaro et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment recommendations for psoriatic arthritis

(2008) C T Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Use of Indirect and Mixed Treatment Comparisons for Technology Assessment

(2008) Alex Sutton et al.   PHARMACOECONOMICS

The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy

(2008) I. Olivieri et al.   RHEUMATOLOGY